Update on Cancer and Central Nervous System Tumor Surveillance in Pediatric NF2 -, SMARCB1 -, and LZTR1 -Related Schwannomatosis
Authors:
- Melissa R. PerrinoMPMelissa R. Perrino
- Marjolijn C.J. JongmansMJMarjolijn C.J. Jongmans
- Gail E. TomlinsonGTGail E. Tomlinson
- Mary-Louise C. GreerMGMary-Louise C. Greer
- Sarah R. ScollonSSSarah R. Scollon
- Sarah G. MitchellSMSarah G. Mitchell
- Jordan R. HansfordJHJordan R. Hansford
- Kris Ann P. SchultzKSKris Ann P. Schultz
- Wendy K. KohlmannWKWendy K. Kohlmann
- Jennifer M. KalishJKJennifer M. Kalish
- Suzanne P. MacFarlandSMSuzanne P. MacFarland
- Anirban DasADAnirban Das
Top Cited Papers
- 12 February 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (8) , 1400-1406
Abstract
Schwannomatosis (SWN) is a distinct cancer predisposition syndrome caused by germline pathogenic variants in the genes NF2, SMARCB1, or LZTR1. There is a significant clinical overlap between these syndromes with the hallmark of increased risk for cranial, spinal, and peripheral schwannomas. Neurofibromatosis type 2 was recently renamed as NF2-related SWN and is the most common SWN syndrome, with increased risk for bilateral vestibular schwannomas, intradermal schwannomas, meningiomas, and less commonly, ependymoma. SMARCB1-related SWN is a familial SWN syndrome associated with peripheral and spinal schwannomas and an increased risk for meningiomas and malignant peripheral nerve sheath tumors, even in the absence of radiation. These individuals do not develop bilateral vestibular schwannomas. Finally, patients with LZTR1-related SWN typically present with peripheral schwannomas, and unilateral vestibular schwannomas have been reported. The following perspective is intended to highlight the clinical presentation and international tumor surveillance recommendations across these SWN syndromes.Keywords
Funding Information
- National Cancer Institute
- American Lebanese Syrian Associated Charities
- Manchester Biomedical Research Centre (NIHR203308)
- Hospital Research Foundation
- McClurg Foundation
- Deutsche Kinderkrebsstiftung (DKS2024.03)
This publication has 56 references indexed in Scilit:
- Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosisSkeletal Radiology, 2019
- Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomasHuman Genetics, 2018
- Multiparametric whole‐body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosisJournal of Magnetic Resonance Imaging, 2016
- Premature termination of SMARCB1 translation may be followed by reinitiation in schwannomatosis-associated schwannomas, but results in absence of SMARCB1 expression in rhabdoid tumorsActa Neuropathologica, 2014
- Relationship between whole‐body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosisAmerican Journal of Medical Genetics Part A, 2014
- Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteriaAmerican Journal of Medical Genetics Part A, 2013
- Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosisSkeletal Radiology, 2011
- Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosisAmerican Journal of Medical Genetics Part A, 2011
- Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumorsPediatric Blood & Cancer, 2010
- Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutationneurogenetics, 2009